Scarica l'app Stockscreener
846.23
3.67%
-31.71
Precedente Chiudi:
$877.94
Aprire:
$828.96
Volume 24 ore:
534.61K
Relative Volume:
1.53
Capitalizzazione di mercato:
$52.12B
Reddito:
$3.06B
Utile/perdita netta:
$1.28B
Rapporto P/E:
43.02
EPS:
19.6719
Flusso di cassa netto:
$447.35M
1 W Prestazione:
-6.11%
1M Prestazione:
-6.85%
6M Prestazione:
+46.35%
1 anno Prestazione:
+39.29%
Intervallo 1D:
$827.52
$853.96
Intervallo di 1 settimana:
$827.52
$904.79
Portata 52W:
$510.06
$934.62
Argen X Se Adr Stock (ARGX) Company Profile
Confronta ARGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
846.59 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.50 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.88 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.05 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.50 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | Ripresa | Truist | Buy |
| 2025-09-11 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-08-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-05-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2025-01-17 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-11-12 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Strong Buy |
| 2024-10-04 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-08-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2024-07-25 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-07-23 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-24 | Downgrade | UBS | Buy → Neutral |
| 2023-07-17 | Ripresa | Evercore ISI | Outperform |
| 2023-06-15 | Iniziato | Societe Generale | Sell |
| 2023-05-31 | Iniziato | UBS | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-14 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | Iniziato | William Blair | Outperform |
| 2022-10-12 | Iniziato | Oppenheimer | Perform |
| 2022-07-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | Ripresa | Stifel | Buy |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-28 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-09-23 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | Iniziato | Deutsche Bank | Hold |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-06-18 | Iniziato | UBS | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | Iniziato | Redburn | Neutral |
| 2021-03-05 | Reiterato | H.C. Wainwright | Neutral |
| 2021-02-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-07-29 | Iniziato | H.C. Wainwright | Neutral |
| 2020-02-10 | Iniziato | BofA/Merrill | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-10-31 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | Iniziato | JP Morgan | Overweight |
| 2019-09-27 | Iniziato | Wells Fargo | Market Perform |
| 2019-09-16 | Ripresa | Cowen | Outperform |
| 2019-06-28 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-18 | Ripresa | SunTrust | Buy |
| 2019-01-04 | Iniziato | Morgan Stanley | Overweight |
| 2018-12-17 | Iniziato | Goldman | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-06-29 | Iniziato | Nomura | Buy |
| 2018-04-09 | Iniziato | SunTrust | Buy |
| 2018-01-29 | Reiterato | JMP Securities | Mkt Outperform |
Mostra tutto
Argen X Se Adr Borsa (ARGX) Ultime notizie
Argenx stock rating maintained at Buy by BofA despite TED trial failure - Investing.com India
argenx stock rating reiterated at Buy by Guggenheim despite TED study halt - Investing.com
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
argenx stock tumbles after discontinuing thyroid eye disease studies - Investing.com
Stifel raises argenx stock price target to $1,248 on Vyvgart dominance By Investing.com - Investing.com South Africa
Stifel raises argenx stock price target to $1,248 on Vyvgart dominance - Investing.com India
Argenx price target raised to $910 from $800 at UBS on Vyvgart growth By Investing.com - Investing.com South Africa
Argenx price target raised to $910 from $800 at UBS on Vyvgart growth - Investing.com India
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Argenx NV ADR stock hits all-time high at $934.62 - Investing.com India
Argenx NV ADR stock hits all-time high at $934.62 By Investing.com - Investing.com South Africa
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today - Sahm
Looking Into argenx SE's Recent Short Interest - Sahm
ClearBridge International Growth ADR ESG Portfolios Q3 2025 Commentary - Seeking Alpha
This Argenx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Oppenheimer raises argenx stock price target to $1,040 on higher Vyvgart sales By Investing.com - Investing.com South Africa
Oppenheimer raises argenx stock price target to $1,040 on higher Vyvgart sales - Investing.com India
Quant Ratings Updated on 141 Stocks - InvestorPlace
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Sahm
Argenx stock reaches all-time high at 915.55 USD By Investing.com - Investing.com Nigeria
Argenx stock reaches all-time high at 915.55 USD - Investing.com
Stocks Showing Improving Market Leadership: argenx ADR Earns 84 RS Rating - MSN
Argenx NV ADR stock hits all-time high of 855.68 USD - Investing.com Nigeria
Argenx NV ADR stock hits all-time high of 855.68 USD By Investing.com - Investing.com South Africa
Janus Henderson Global Life Sciences Fund Q3 2025 Commentary - Seeking Alpha
argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada - Barchart.com
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View - Finviz
Piper Sandler raises argenx stock price target to $930 on strong Vyvgart sales By Investing.com - Investing.com South Africa
Piper Sandler raises argenx stock price target to $930 on strong Vyvgart sales - Investing.com
Vyvgart Fuels Strong Growth for Argenx and Supports Developing Pipeline - Morningstar
argenx SE stock price target raised to $1,146 from $800 at TD Cowen By Investing.com - Investing.com South Africa
argenx SE stock price target raised to $1,146 from $800 at TD Cowen - Investing.com India
argenx ADR earnings beat by $0.74, revenue topped estimates - Investing.com Canada
Argenx rises after Q3 earnings beat on strong sales growth By Investing.com - Investing.com South Africa
Argen X Se Adr Azioni (ARGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.38%
4.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):